These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 31210393

  • 1. GCV/VCVG prophylaxis against CMV DNAemia in pediatric renal transplant patients: A systematic review and meta-analysis.
    Chatani B, Glaberson W, Nemeth Z, Tamariz L, Gonzalez IA.
    Pediatr Transplant; 2019 Sep; 23(6):e13514. PubMed ID: 31210393
    [Abstract] [Full Text] [Related]

  • 2. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
    Paulsen G, Cumagun P, Mixon E, Fowler K, Feig D, Shimamura M.
    Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
    [Abstract] [Full Text] [Related]

  • 3. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 4. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight-based dosed valganciclovir prophylaxis.
    Liverman R, Serluco A, Nance G, George R, Rodriguez DS, Deshpande S, Mao C, Garro R, Yildirim I.
    Pediatr Transplant; 2023 Jun; 27(4):e14493. PubMed ID: 36945819
    [Abstract] [Full Text] [Related]

  • 5. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
    Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J.
    Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
    [Abstract] [Full Text] [Related]

  • 6. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
    Heldenbrand S, Li C, Cross RP, DePiero KA, Dick TB, Ferguson K, Kim M, Newkirk E, Park JM, Sudaria-Kerr J, Tichy EM, Ueda KR, Weng R, Wisniewski J, Gabardi S.
    Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
    [Abstract] [Full Text] [Related]

  • 7. Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
    Schaenman J, Phonphok K, Spanuchart I, Duong T, Sievers TM, Lum E, Reed EF, Bunnapradist S.
    Transpl Infect Dis; 2021 Feb; 23(1):e13457. PubMed ID: 32892447
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
    Park JM, Lake KD, Arenas JD, Fontana RJ.
    Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
    [Abstract] [Full Text] [Related]

  • 9. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
    Fleming JN, Taber DJ, Weimert NA, Nadig S, McGillicuddy JW, Bratton CF, Baliga PK, Chavin KD.
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
    [Abstract] [Full Text] [Related]

  • 10. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B, Zencke S, Krupka K, Fichtner A, Pape L, Dello Strologo L, Guzzo I, Topaloglu R, Kranz B, König J, Bald M, Webb NJ, Noyan A, Dursun H, Marks S, Yalcinkaya F, Thiel F, Billing H, Pohl M, Fehrenbach H, Bruckner T, Tönshoff B.
    Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
    [Abstract] [Full Text] [Related]

  • 11. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
    Transplantation; 2011 Jul 27; 92(2):217-23. PubMed ID: 21685829
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
    Cameron BM, Kennedy SE, Rawlinson WD, Mackie FE.
    Pediatr Transplant; 2017 Feb 27; 21(1):. PubMed ID: 27704725
    [Abstract] [Full Text] [Related]

  • 13. Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis.
    Das BB, Prusty BK, Niu J, Sue PK.
    Pediatr Transplant; 2020 Dec 27; 24(8):e13750. PubMed ID: 32573886
    [Abstract] [Full Text] [Related]

  • 14. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D, Nguyen MH, Kwak EJ, Silveira FP, Vadnerkar A, Pilewski J, Crespo M, Toyoda Y, Bermudez C, Clancy CJ.
    J Heart Lung Transplant; 2010 Sep 27; 29(9):1014-20. PubMed ID: 20598582
    [Abstract] [Full Text] [Related]

  • 15. Low-Dose Valganciclovir Prophylaxis Is Safe and Cost-Saving in CMV-Seropositive Kidney Transplant Recipients.
    Shi Y, Lerner AH, Rogers R, Vieira K, Merhi B, Mecadon K, Osband AJ, Bayliss G, Gohh R, Morrissey P, Farmakiotis D.
    Prog Transplant; 2021 Dec 27; 31(4):368-376. PubMed ID: 34839729
    [Abstract] [Full Text] [Related]

  • 16. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
    Reischig T, Vlas T, Kacer M, Pivovarcikova K, Lysak D, Nemcova J, Drenko P, Machova J, Bouda M, Sedivcova M, Kormunda S.
    J Am Soc Nephrol; 2023 May 01; 34(5):920-934. PubMed ID: 36749127
    [Abstract] [Full Text] [Related]

  • 17. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Brady RL, Green K, Frei C, Maxwell P.
    Transpl Infect Dis; 2009 Apr 01; 11(2):106-11. PubMed ID: 19054381
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Antiviral Agents in Preventing Allograft Rejection Following CMV Prophylaxis in High-Risk Kidney Transplantation: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Ruenroengbun N, Sapankaew T, Chaiyakittisopon K, Phoompoung P, Ngamprasertchai T.
    Front Cell Infect Microbiol; 2022 Apr 01; 12():865735. PubMed ID: 35433502
    [Abstract] [Full Text] [Related]

  • 19. Comparison of standard versus low-dose valganciclovir regimens for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
    Bixby AL, Fitzgerald L, Park JM, Kaul D, Tischer S.
    Transpl Infect Dis; 2021 Oct 01; 23(5):e13713. PubMed ID: 34428337
    [Abstract] [Full Text] [Related]

  • 20. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D, Ogawa Y, Fujita H, Morita K, Sasaki H, Oishi Y, Higuchi H, Hatanaka K, Shinohara N.
    Nephrology (Carlton); 2016 Jul 01; 21 Suppl 1():63-6. PubMed ID: 26970406
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.